REAL

DermAll nanomedicine for allergen-specific immunotherapy

Garaczi, Edina and Szabó, Kornélia and Francziszti, László and Csiszovszki, Zsolt and Lőrincz, Orsolya and Tőke, Enikő Rita and Molnár, Levente and Bitai, Tamás and Jánossy, Tamás and Bata-Csörgő, Zsuzsanna and Kemény, Lajos and Lisziewicz, Julianna (2013) DermAll nanomedicine for allergen-specific immunotherapy. Nanomedicine: Nanotechnology, Biology and Medicine, 9 (8). pp. 1245-1254. ISSN 1549-9634

[img] Text
1-s2.0-S1549963413002621-main.pdf
Restricted to Repository staff only

Download (1296Kb)

Abstract

Allergen-specific immunotherapy (ASIT) the only disease-modifying treatment for IgE-mediated allergies is characterized with long treatment duration and high risk of side effects. We investigated the safety, immunogenicity and efficacy of a novel ASIT, called DermAll, in an experimental allergic rhinitis model. We designed and characterized DermAll-OVA, a synthetic plasmid pDNA/PEIm nanomedicine expressing ovalbumin (OVA) as model allergen. DermAll-OVA was administered topically with DermaPrep device to target Langerhans cells. To detect the clinical efficacy of DermAll ASIT we quantified the nasal symptoms and characterized the immunomodulatory activity of DermAll ASIT by measuring cytokine secretion after OVA-stimulation of splenocytes and antibodies from the sera. In allergic mice DermAll ASIT was as safe as Placebo, balanced the allergen-induced pathogenic TH2-polarized immune responses, and decreased the clinical symptoms by 52% [32%, 70%] compared to Placebo. These studies suggest that DermAll ASIT is safe and should significantly improve the immunopathology and symptoms of allergic diseases.

Item Type: Article
Subjects: R Medicine / orvostudomány > R1 Medicine (General) / orvostudomány általában
Depositing User: Dr. Kornélia Szabó
Date Deposited: 25 Sep 2014 13:44
Last Modified: 25 Sep 2014 13:44
URI: http://real.mtak.hu/id/eprint/16777

Actions (login required)

View Item View Item